checkAd

Chart

Technische Analyse in EUR

52 Wochen
Tief
2,410
Hoch
20,000
200 Tage
Tief
2,410
Hoch
20,000
Heute
Tief
18,900
Hoch
20,000

Neuigkeiten

ZeitTitel
SmartbrokerSmartbroker: Ab 0€ pro Order handeln mit dem Testsieger (Finanztest 11/2020) Anzeige
06.07.21
Avatar opportoni schrieb:
05.04.21Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone
globenewswire | Weitere Nachrichten
31.03.21Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
globenewswire | Weitere Nachrichten
22.03.21Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.
globenewswire | Weitere Nachrichten
04.03.21Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
globenewswire | Weitere Nachrichten
22.02.21Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021
globenewswire | Weitere Nachrichten
08.02.21Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
globenewswire | Weitere Nachrichten
14.12.20Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
globenewswire | Weitere Nachrichten
10.12.20Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
globenewswire | Weitere Nachrichten
07.12.20Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors
globenewswire | Weitere Nachrichten
12.11.20Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update
globenewswire | Weitere Nachrichten
02.11.20Opiant Pharmaceuticals to Participate at the Jefferies 2020 Virtual London Healthcare Conference
globenewswire | Weitere Nachrichten
27.10.20Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
globenewswire | Weitere Nachrichten
Insidertrade: :

Community

Aktienkurs

BörsenplatzTradegate
Letzter Kurs18,900EUR
Performance-4,55 %
Kurszeit17.09.21
Eröffnung20,000EUR
Tageshoch20,000EUR
Tagestief18,900EUR
Vortageskurs19,800EUR
Volumen25,00Stk.
52-Wochen Hoch20,000EUR
52-Wochen Tief2,410EUR
Anzahl Trades1
Performance 1 Monat+40,46 %

Performance

ZeitKursPerf.
1 Tag18,900EUR
-4,55 %
1 Woche15,000EUR
+22,67 %
1 Monat13,100EUR
+40,46 %

Stammdaten

NameOpiant Pharmaceuticals Inc
KurznameOpiant Pharmact
NamenszusatzRegistered Shs
KategorieAktien
AktientypStammaktien
WKNA2AFQ6
Symbol8OP
BrancheDienstleistungen
LandUSA USA
ReferenzwährungUSD
Aktienanzahl4,40 Mio.
Marktkapitalisierung83,15 Mio.EUR

Kontaktdaten

NameOpiant Pharmaceuticals Inc
LandUSA USA
Webseitewww.opiant.com

Aktionäre interessieren sich auch für:

#WertpapierPerf. %
1.-1,48
2.+1,26
3.0,00
 
4.+0,03
5.+2,17
6.-1,42
7.+1,72
8.+3,74
9.-2,06
10.+0,42